Glaxosmithkline receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
GSK plc (GSK)
Track today's live GSK plc (GSK) share price, performance and key data on this page with our current London:GSK stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the GSK plc share price on the London exchange. Use the dropdown to switch exchange for the GSK share price, head to our technical summary section, which provides analysis on GSK plc share price buy/sell indicators using real-time data (or discuss the GSK plc (GSK) stock price today with other investors in the GSK plc LON share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current LON:GSK share price (ISIN: GB00BN7SWP63) to enhance your trading decisions with our free investment tools and resources.
What Is the GSK plc Share Price Today?
The GSK plc share price today is 1,942.00.
What Is the Stock Symbol for GSK plc
The stock symbol (or 'ticker') for Glaxosmithkline Plc is "GSK."
What Stock Exchange Does GSK plc Trade On?
Glaxosmithkline Plc is listed and trades on the London stock exchange.
Is GSK plc a Good Stock to Buy?
Determining whether GSK plc (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current LON:GSK share price (ISIN: GB00BN7SWP63) to enhance your trading decisions with our free investment tools and resources.
What Is the GSK plc Share Price Today?
The GSK plc share price today is 1,942.00.
What Is the Stock Symbol for GSK plc
The stock symbol (or 'ticker') for Glaxosmithkline Plc is "GSK."
What Stock Exchange Does GSK plc Trade On?
Glaxosmithkline Plc is listed and trades on the London stock exchange.
Is GSK plc a Good Stock to Buy?
Determining whether GSK plc (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
1,936.00
-45.00(-2.27%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1,936.00
1,992.50
52 wk Range
1,315.00
2,282.00
GSK is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1,936.001,992.50
52 wk Range
1,315.002,282.00
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(3.38%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(3.38%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
GSK Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Neutral
Price Target
2,093.21
Upside
+8.12%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a low P/E ratio relative to near-term earnings growth
- Glaxosmithkline receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form 6K GSK plc For: 23 June
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
5 Buy
12 Hold
4 Sell
Ratings:
21 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 2,093.21
(+8.12% Upside)
Earnings
Latest Release
29/04/2026
EPS / Forecast
0.47 / 0.43
Revenue / Forecast
7.63B / 7.64B
Compare GSK to Peers and Sector
Metrics to compare | GSK | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGSKPeersSector | |
|---|---|---|---|---|
P/E Ratio | 13.5x | 21.3x | −0.4x | |
PEG Ratio | 0.16 | 0.48 | 0.00 | |
Price/Book | 4.4x | 4.9x | 2.6x | |
Price / LTM Sales | 2.4x | 3.1x | 3.0x | |
Upside (Analyst Target) | −1.1% | 24.1% | 53.6% | |
Fair Value Upside | Unlock | 13.8% | 7.6% | Unlock |
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases; and strategic research collaboration with Engitix Ltd. to identify and validate novel therapeutic targets driving liver fibrosis regression. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the GSK plc (London: GSK) Share Price Today?
The GSK plc stock price today is 1,936.00 GBP.
What Stock Exchange Does GSK plc (GSK) Trade On?
GSK plc is listed and trades on the London Stock Exchange.
What Is the Ticker (Stock Symbol) for GSK plc?
The stock symbol (also called a 'ticker') for GSK plc is "GSK."
Does GSK plc Pay Dividends? What’s The Current GSK Dividend Yield?
Yes, GSK Pays Dividends to its Shareholders. The current GSK plc dividend yield is 3.38%.
What Is the Current GSK plc Market Capitalisation?
As of today, GSK plc (London: GSK) market cap is 77.32B GBP.
What Is GSK plc's (GSK) Earnings Per Share (TTM)?
The GSK plc EPS is currently 1.42 (Trailing Twelve Months).
When Is the Next GSK plc Earnings Date?
GSK plc's next earnings report will be released on 28/07/2026.
Is GSK a Buy or Sell From a Technical Analyst Perspective?
Based on today's GSK plc moving averages and other technical indicators, the daily buy/sell signal for GSK stock is Neutral.
How Many Times Has GSK plc Stock Split?
GSK plc has split 1 times. (See the GSK stock split history page for full effective split date and price information.)
How Many Employees Does GSK plc Have?
GSK plc has 66841 employees, based on their latest Companies House report.
What is the current trading status of GSK plc (London: GSK)?
As of 01/07/2026, GSK plc (GSK) is trading at a share price of 1,936.00 GBP, with a previous close of 1,981.00 GBP. The stock has fluctuated within a day range of 1,936.00 GBP to 1,992.50 GBP, while its 52-week range spans from 1,315.00 GBP to 2,282.00 GBP.
What Is GSK plc (GSK) Price Target According to Analysts?
The average 12-month price target for GSK plc is 2,093.21 GBP, with a high estimate of 2825 GBP and a low estimate of 1455 GBP. 5 analysts recommend buying the stock, while 4 suggest selling, leading to an overall rating of Neutral. The stock has an +8.12% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.